Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Branka Petričević, Johannes Laengle, Erika Jensen-Jarolim, Josef Singer, Judit Fazekas, Monika Sachet, Rupert Bartsch, Michael Bergmann, Guenther G. Steger
Publikováno v:
Journal of Translational Medicine
Background Monoclonal antibodies (mAb), such as trastuzumab are a valuable addition to breast cancer therapy. Data obtained from neoadjuvant settings revealed that antibody-dependent cell-mediated cytotoxicity (ADCC) is a major mechanism of action fo
Publikováno v:
Journal of Translational Medicine
Background Malignancies induce changes in the levels of serum amino acids (AA), which may offer diagnostic potential. Furthermore, changes in AA levels are associated with immune cell function. In this study, serum AA levels were studied in breast ca
Autor:
Yang Shixin, Yi Zhan, Xiu-Wu Bian, Xinhua Yang, Wings T.Y. Loo, Jun Jiang, Fan Zhang, Li Chen, Hua-Liang Xiao, Louis W.C. Chow, Qing-liang Wang, Linjun Fan, Jin-Long Wu
Publikováno v:
Journal of Translational Medicine
Background Biological molecular markers such as proto-oncogene erbB-2 (HER-2/neu, c-erbB-2), the CXC chemokine receptor 4 (CXCR4), estrogen receptor (ER), Proliferating Cell Nuclear Antigen (PCNA), DNA topoisomerase II (topo II), P-glycoprotein (P-gp
Autor:
Erika, Hamilton, Kimberly, Blackwell, Amy C, Hobeika, Timothy M, Clay, Gloria, Broadwater, Xiu-Rong, Ren, Wei, Chen, Henry, Castro, Frederic, Lehmann, Neil, Spector, Junping, Wei, Takuya, Osada, H Kim, Lyerly, Michael A, Morse
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 10, Iss 1, p 28 (2012)
Journal of Translational Medicine, Vol 10, Iss 1, p 28 (2012)
Background Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease. HER2-based v
Autor:
P. Arapantoni, Dimitrios Vlachodimitropoulos, Olympia Tzaida, Mattheos Bobos, Christos Valavanis, Konstantine T. Kalogeras, Christos Christodoulou, Gerasimos Aravantinos, George Pentheroudakis, Anna Batistatou, Anastasia G Eleftheraki, Vassiliki Kotoula, Nikolaos Soupos, Dimitrios Pectasides, Ralph M. Wirtz, Eleni Timotheadou, George Fountzilas, Genovefa Polychronidou, Angelos Koutras, Ralf Kronenwett, Helen Gogas
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 10, Iss 1, p 10 (2012)
Journal of Translational Medicine, Vol 10, Iss 1, p 10 (2012)
Background HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively evaluate the prognostic/predictiv